The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline
Disproportionality analyses are the most-commonly used study design used in the post-marketing phase to detect suspected adverse drug reactions in individual case safety reports. Recent years have witnessed an exponential increase in published articles on disproportionality analyses, thanks to publi...
Saved in:
| Main Authors: | Michele Fusaroli, Francesco Salvo, Charles Khouri, Emanuel Raschi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1488725/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01) -
A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01) -
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
by: Paola Maria Cutroneo, et al.
Published: (2024-01-01) -
A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024-11-01) -
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)